




Instance: composition-en-174da4bc3583312132255c6ab13da6ac
InstanceOf: CompositionUvEpi
Title: "Composition for ferriprox Package Leaflet"
Description:  "Composition for ferriprox Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp174da4bc3583312132255c6ab13da6ac)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ferriprox"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Ferriprox is and what it is used for </li>
<li>What you need to know before you take Ferriprox </li>
<li>How to take Ferriprox </li>
<li>Possible side effects </li>
<li>How to store Ferriprox </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What ferriprox is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What ferriprox is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ferriprox contains the active substance deferiprone. Ferriprox is an iron chelator, a type of medicine 
that removes excess iron from the body. </p>
<p>Ferriprox is used to treat iron overload caused by frequent blood transfusions in patients with 
thalassaemia major when current chelation therapy is contraindicated or inadequate. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take ferriprox"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take ferriprox"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Ferriprox </p>
<p>if you are allergic to deferiprone or any of the other ingredients of this medicine (listed in 
section 6). </p>
<p>if you have a history of repeated episodes of neutropenia (low white blood cell (neutrophil) 
count). </p>
<p>if you have a history of agranulocytosis (very low white blood cell (neutrophil) count). </p>
<p>if you are currently taking medicines known to cause neutropenia or agranulocytosis (see  Other 
medicines and Ferriprox ). </p>
<p>if you are pregnant or breast-feeding. </p>
<p>Warnings and precautions </p>
<p>the most serious side effect that may occur while taking Ferriprox is a very low white blood cell 
(neutrophil) count. This condition, known as severe neutropenia or agranulocytosis, has 
occurred in 1 to 2 out of 100 people who have taken Ferriprox in clinical studies. Because white 
blood cells help to fight infection, a low neutrophil count may place you at risk of developing a 
serious and potentially life-threatening infection. To monitor for neutropenia, your doctor will 
ask you to have a blood test (to check your white blood cell count) performed regularly, as 
frequently as every week, while you are being treated with Ferriprox. It is very important for 
you to keep all of these appointments. Please refer to the patient card attached to the carton. If </p>
<p>you get any symptoms of infection such as fever, sore throat or flu-like symptoms, immediately 
seek medical attention. Your white blood cell count must be checked within 24 hours in order to 
detect potential agranulocytosis. </p>
<p>if you are human immunodeficiency virus (HIV) positive or if your liver or kidney function is 
severely impaired, your doctor may recommend additional tests. </p>
<p>Your doctor will also ask you to come in for tests to monitor body iron load. In addition he or she 
might ask you to undergo liver biopsies. </p>
<p>Other medicines and Ferriprox 
Do not take medicines known to cause neutropenia or agranulocytosis (see  Do not take Ferriprox ). 
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other 
medicines, including medicines obtained without a prescription. </p>
<p>Do not take aluminium-based antacids at the same time as taking Ferriprox. </p>
<p>Please consult with your doctor or pharmacist before taking vitamin C with Ferriprox. </p>
<p>Pregnancy and breast-feeding 
Ferriprox may cause harm to unborn babies when used by pregnant women. Ferriprox must not be 
used during pregnancy unless clearly necessary. If you are pregnant or you become pregnant during 
treatment with Ferriprox, get medical advice immediately. </p>
<p>Both female and male patients are recommended to take special precautions in their sexual activity if 
there is any possibility for pregnancy to occur: Women of childbearing potential are recommended to 
use effective contraception during treatment with Ferriprox and for 6 months after the last dose. Men 
are recommended to use effective contraception during treatment and for 3 months after the last dose. 
This should be discussed with your doctor. </p>
<p>Do not use Ferriprox if you are breast-feeding. Please refer to the patient card attached to the carton. </p>
<p>Driving and using machines 
Not relevant. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take ferriprox"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take ferriprox"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. The amount of Ferriprox that you take will depend on your weight. The usual dose 
is 25 mg/kg, 3 times per day, for a total daily dose of 75 mg/kg. The total daily dose should not exceed 
100 mg/kg. Take your first dose in the morning. Take your second dose midday. Take your third dose 
in the evening. Ferriprox can be taken with or without food; however, you may find it easier to 
remember to take Ferriprox if you take it with your meals. </p>
<p>If you take more Ferriprox than you should 
There are no reports of acute overdose with Ferriprox. If you have accidentally taken more than the 
prescribed dose, you should contact your doctor. </p>
<p>If you forget to take Ferriprox 
Ferriprox will be most effective if you do not miss any doses. If you do miss one dose take it as soon 
as you remember and take your next dose at its regularly scheduled time. If you miss more than one 
dose do not take a double dose to make up for forgotten individual doses, just continue with your 
normal schedule. Do not change your daily dose without first talking to your doctor. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The most serious side effect of Ferriprox is a very low white blood cell (neutrophil) count. This 
condition, known as severe neutropenia or agranulocytosis, has occurred in 1 to 2 out of 100 people 
who have taken Ferriprox in clinical studies. A low white blood cell count can be associated with a 
serious and potentially life-threatening infection. Report immediately to your doctor any symptoms of 
infection such as: fever, sore throat or flu-like symptoms. </p>
<p>Very common side effects (may affect more than 1 in 10 people): </p>
<p>abdominal pain; </p>
<p>nausea; </p>
<p>vomiting; </p>
<p>reddish/brown discolouration of urine. </p>
<p>If you experience nausea or vomiting, it may help to take your Ferriprox with some food. Discoloured 
urine is a very common effect and is not harmful. </p>
<p>Common side effects (may affect up to 1 in 10 people): </p>
<p>low white blood cell count (agranulocytosis and neutropenia); </p>
<p>headache; </p>
<p>diarrhoea; </p>
<p>increase in liver enzymes; </p>
<p>fatigue; </p>
<p>increase in appetite. </p>
<p>Not known (frequency cannot be estimated from the available data): </p>
<p>allergic reactions including skin rash or hives. </p>
<p>Events of joint pain and swelling ranged from mild pain in one or more joints to severe disability. In 
most cases, the pain disappeared while patients continued taking Ferriprox. </p>
<p>Neurological disorders (such as tremors, walking disorders, double vision, involuntary muscle 
contractions, problems with movement coordination) have been reported in children who had been 
voluntarily prescribed more than double the maximum recommended dose of 100 mg/kg/day for 
several years and have also been observed in children with standard doses of deferiprone. The children 
recovered from these symptoms after Ferriprox discontinuation. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store ferriprox"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store ferriprox"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the label after EXP. 
The expiry date refers to the last day of that month. </p>
<p>Do not store above 30  C. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Ferriprox contains 
The active substance is deferiprone. Each 500 mg tablet contains 500 mg deferiprone. </p>
<p>The other ingredients are:<br />
tablet core: microcrystalline cellulose, magnesium stearate, colloidal anhydrous silica 
coating: hypromellose, macrogol, titanium dioxide </p>
<p>What Ferriprox looks like and contents of the pack 
White to off-white, capsule-shaped, film-coated tablet imprinted  APO  bisect  500  on one side, 
plain on the other. The tablet is 7.1 mm x 17.5 mm x 6.8 mm and scored. The tablet can be divided 
into equal halves. Ferriprox is packaged in bottles of 100 tablets. </p>
<p>Marketing Authorisation Holder: 
Chiesi Farmaceutici S.p.A. 
Via Palermo 26/A<br />
43122 Parma<br />
Italy </p>
<p>Manufacturer: 
Eurofins PROXY Laboratories B.V. 
Archimedesweg 2333 CM Leiden 
Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Chiesi sa/nv<br />
T l/Tel: + 32 (0)2 788 42 Lietuva 
Chiesi Pharmaceuticals GmbH<br />
Tel: + 43 1 4073<br />
Chiesi Bulgaria EOOD<br />
 .: +359 29201Luxembourg/Luxemburg 
Chiesi sa/nv 
T l/Tel: + 32 (0)2 788 42  esk  republika 
Chiesi CZ s.r.o. 
Tel: + 420 261221Magyarorsz g 
Chiesi Hungary Kft. 
Tel.: + 36-1-429 1Danmark 
Chiesi Pharma AB 
Tlf: + 46 8 753 35 Malta 
Chiesi Farmaceutici S.p.A. 
Tel: + 39 0521 2Deutschland 
Chiesi GmbH 
Tel: + 49 40 89724-0 </p>
<p>Nederland 
Chiesi Pharmaceuticals B.V. 
Tel: + 31 88 501 64 Eesti 
Chiesi Pharmaceuticals GmbH 
Tel: + 43 1 4073Norge 
Chiesi Pharma AB 
Tlf: + 46 8 753 35 <br />
DEMO ABEE 
 : + 30 210 8161 sterreich 
Chiesi Pharmaceuticals GmbH 
Tel: + 43 1 4073Espa a 
Chiesi Espa a, S.A.U. 
Tel: + 34 93 494 8Polska 
Chiesi Poland Sp. z.o.o. 
Tel.: + 48 22 620 1France 
Chiesi S.A.S. 
T l: + 33 1 47688Portugal 
Chiesi Farmaceutici S.p.A. 
Tel: + 39 0521 2Hrvatska 
Chiesi Pharmaceuticals GmbH 
Tel: + 43 1 4073Rom nia 
Chiesi Romania S.R.L. 
Tel: + 40 212023Ireland 
Chiesi Farmaceutici S.p.A. 
Tel: + 39 0521 2Slovenija 
CHIESI SLOVENIJA, d.o.o. 
Tel: + 386-1-43 00  sland 
Chiesi Pharma AB 
S mi: +46 8 753 35 Slovensk  republika 
Chiesi Slovakia s.r.o. 
Tel: + 421 259300Italia 
Chiesi Italia S.p.A. 
Tel: + 39 0521 2Suomi/Finland 
Chiesi Pharma AB 
Puh/Tel: +46 8 753 35 <br />
The Star Medicines Importers Co. Ltd. 
 : + 357 25 371Sverige 
Chiesi Pharma AB 
Tel: +46 8 753 35 Latvija 
Chiesi Pharmaceuticals GmbH 
Tel: + 43 1 4073United Kingdom (Northern Ireland) 
Chiesi Farmaceutici S.p.A. 
Tel: + 39 0521 2This leaflet was last revised in . </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-174da4bc3583312132255c6ab13da6ac
InstanceOf: CompositionUvEpi
Title: "Composition for ferriprox Package Leaflet"
Description:  "Composition for ferriprox Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp174da4bc3583312132255c6ab13da6ac)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ferriprox"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Ferriprox 
3. Sådan skal du tage Ferriprox 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What ferriprox is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What ferriprox is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ferriprox indeholder det aktive stof deferipron. Ferriprox er en jernchelator, dvs. en type medicin, der 
fjerner overskydende jern fra kroppen. </p>
<p>Ferriprox bruges til at behandle jernophobning som følge af hyppige blodtransfusioner hos talassæmi-
patienter, hvor nuværende kelationsterapi er kontraindiceret eller utilstrækkelig.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take ferriprox"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take ferriprox"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Ferriprox 
− 
hvis du er allergisk over for deferipron eller et af de øvrige indholdsstoffer i Ferriprox (angivet i 
punkt 6). 
− 
hvis du har haft gentagne episoder med neutropeni (et lavt antal hvide blodlegemer 
(neutrofiler)). 
− 
hvis du har haft agranulocytose (et meget lavt antal hvide blodlegemer (neutrofiler)). 
− 
hvis du tager medicin, der vides at kunne forårsage neutropeni eller agranulocytose (se pkt. 
“Anden medicin og Ferriprox"). 
− 
hvis du er gravid eller ammer. </p>
<p>Advarsler og forsigtighedsregler 
− 
de alvorligste bivirkninger, som kan fremkomme, mens du tager Ferriprox, er et meget lavt antal 
hvide blodlegemer (neutrofiler). Denne tilstand, som kaldes svær neutropeni eller 
agranulocytose, optrådte hos 1 til 2 ud af 100 personer, som tog Ferriprox i kliniske studier. Da 
hvide blodlegemer hjælper med at bekæmpe infektioner, vil et lavt antal neutrofiler udsætte dig 
for en risiko for at udvikle en alvorlig eller evt. livstruende infektion. Din læge vil bede dig om 
at få taget en blodprøve for at undersøge for neutropeni (kontrollere antallet af hvide 
blodlegemer) regelmæssigt, så ofte som hver uge, mens du behandles med Ferriprox. Det er 
meget vigtigt, at du overholder alle disse aftaler. Se patientkortet, som er hæftet på denne æske. 
Søg straks læge, hvis du får symptomer på infektion som f.eks. feber, ondt i halsen eller 
influenzalignende symptomer. Antallet af hvide blodlegemer skal kontrolleres inden for et døgn 
for at opdage potentiel agranulocytose. 
− 
hvis du er human immundefektvirus (hiv)-positiv, eller hvis din lever- eller nyrefunktion er 
kraftigt nedsat, kan din læge anbefale yderligere undersøgelser. </p>
<p>Din læge vil også bede dig møde til undersøgelser for at kontrollere din krops jernbelastning. 
Derudover kan han eller hun måske bede dig få taget nogle leverbiopsier. </p>
<p>Brug af anden medicin sammen med Ferriprox 
Du må ikke tage medicin, der vides at forårsage neutropeni eller agranulocytose (se pkt. “Tag ikke 
Ferriprox"). Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig 
har taget anden medicin eller planlægger at tage anden medicin. Dette gælder også medicin, som ikke 
er købt på recept. </p>
<p>Tag ikke aluminiumbaserede syreneutraliserende midler, samtidig med at du tager Ferriprox. </p>
<p>Kontakt din læge eller apotekspersonalet, før du tager ascorbinsyre (C-vitamin) sammen med 
Ferriprox. </p>
<p>Graviditet og amning 
Ferriprox kan forårsage skade på ufødte børn, hvis det bruges af gravide kvinder. Ferriprox må ikke 
bruges under graviditeten, medmindre det er klart nødvendigt. Hvis du er gravid eller du bliver gravid 
under behandlingen med Ferriprox, skal du straks søge medicinsk rådgivning. </p>
<p>Det anbefales, at både kvindelige og mandlige patienter tager særlige sikkerhedsforanstaltninger under 
deres seksuelle aktivitet, hvis der er nogen mulighed for, at en graviditet kan opstå: Det anbefales, at 
kvinder i den fertile alder bruger effektive præventionsmidler under behandlingen med Ferriprox og i 
6 måneder efter den sidste dosis. Det anbefales, at mænd bruger effektive præventionsmidler under 
behandlingen, og i 3 måneder efter den sidste dosis. Dette skal drøftes med lægen. </p>
<p>Brug ikke Ferriprox, hvis du ammer. Referér venligst til det patientkort, der er påsat denne æske. </p>
<p>Trafik- og arbejdssikkerhed 
Ikke relevant. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take ferriprox"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take ferriprox"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. Den mængde Ferriprox, du tager, afhænger af din vægt. Den normale dosis er 
25 mg/kg, 3 gange daglig, for en total daglig dosis på 75 mg/kg. Den totale daglige dosis bør ikke 
overstige 100 mg/kg. Tag den første dosis om morgenen. Tag den anden dosis midt på dagen. Tag den 
tredje dosis om aftenen. Ferriprox kan tages med eller uden mad; det kan dog være lettere for dig at 
huske at tage Ferriprox, hvis du tager det sammen med dine måltider. </p>
<p>Hvis du har taget for meget Ferriprox 
Der foreligger ingen indberetninger om akut overdosering med Ferriprox. Hvis du ved en fejltagelse 
har indtaget mere end den anbefalede dosis, skal du kontakte din læge. </p>
<p>Hvis du har glemt at tage Ferriprox 
Ferriprox er mest effektivt, hvis du ikke springer nogen doser over. Hvis du har sprunget en dosis 
over, skal du tage den så snart, du kommer i tanker om det, og så tage den næste dosis til det normalt 
planlagte tidspunkt. Hvis du springer mere end én dosis over, må du ikke tage en dobbeltdosis som 
erstatning for glemte enkeltdoser, du skal blot fortsætte efter den normale behandlingsplan. Foretag 
ikke ændringer i den daglige dosering, uden først at have talt med lægen. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Den alvorligste bivirkning ved Ferriprox er et meget lavt antal hvide blodlegemer (neutrofiler). Denne 
tilstand, der betegnes som alvorlig neutropeni eller agranulocytose, er forekommet hos 1 til 2 ud af 
100 patienter, som har taget Ferriprox i studier med patienter. Et lavt antal hvide blodlegemer kan 
være forbundet med en alvorlig og måske livstruende infektion. Kontakt straks din læge, hvis du har 
symptomer på infektion såsom feber, ondt i halsen eller influenzalignende symptomer. </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 behandlede):</p>
<ul>
<li>mavesmerter, </li>
<li>kvalme, </li>
<li>opkastning, </li>
<li>rødbrun misfarvning af urinen. </li>
</ul>
<p>Hvis du får kvalme eller kaster op, kan det måske hjælpe at indtage Ferriprox sammen med mad. 
Misfarvet urin er en meget almindelig bivirkning og er ikke skadelig. </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 behandlede):</p>
<ul>
<li>lavt antal hvide blodlegemer (agranulocytose og neutropeni), </li>
<li>hovedpine, </li>
<li>diarré, </li>
<li>stigning i leverenzymer, </li>
<li>træthed, </li>
<li>forøget appetit. </li>
</ul>
<p>Ikke kendt (hyppigheden kan ikke skønnes fra de tilgængelige data):</p>
<ul>
<li>allergiske reaktioner som f.eks. hududslæt eller nældefeber. </li>
</ul>
<p>Ledsmerte og hævelse spændende fra let smerte i et eller flere led til alvorlig funktionsnedsættelse. I 
de fleste tilfælde forsvandt smerten, selv om patienterne fortsatte med at tage Ferriprox. </p>
<p>Nerveforstyrrelser (såsom tremor, gangforstyrrelser, dobbeltsyn, ufrivillige muskelsammentrækninger, 
problemer med bevægelseskoordination) er rapporteret hos børn, som igennem flere år frivilligt har 
fået ordineret mere end 2 gange den maksimalt anbefalede dosis på 100 mg/kg/dag, og er også 
observeret hos børn ved standarddoser af deferipron. Disse symptomer forsvandt, når børnene ophørte 
med at tage Ferriprox. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store ferriprox"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store ferriprox"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter EXP. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30 ºC. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ferriprox indeholder: 
Aktivt stof: deferipron. Hver 500 mg tablet indeholder 500 mg deferipron. </p>
<p>Øvrige indholdsstoffer: 
tabletkerne: mikrokrystallinsk cellulose, magnesiumstearat, kolloid silica, vandfri. 
tabletovertræk: hypromellose, macrogol, titandioxid. </p>
<p>Udseende og pakningsstørrelser 
Hvid til off-white, kapselformet, filmovertrukket tablet påtrykt “APO" på den ene halvdel og “500" på 
den anden, uden påtryk på bagsiden. Tabletten er 7,1 mm x 17,5 mm x 6,8 mm og har delekærv. 
Tabletten kan deles i to lige store dele. Ferriprox er pakket i glas med 100 tabletter. </p>
<p>Indehaver af markedsføringstilladelsen: 
Chiesi Farmaceutici S.p.A. 
Via Palermo 26/A 
43122 Parma 
Italien </p>
<p>Fremstiller: 
Eurofins PROXY Laboratories B.V. 
Archimedesweg 2333 CM Leiden 
Holland </p>
<p>Hvis du ønsker yderligere oplysninger om Ferriprox, skal du henvende dig til den lokale repræsentant 
for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Chiesi sa/nv<br />
Tél/Tel: + 32 (0)2 788 42<br />
Lietuva 
Chiesi Pharmaceuticals GmbH<br />
Tel: + 43 1 4073919  </p>
<p>България 
Chiesi Bulgaria EOOD<br />
Тел.: +359 29201205  </p>
<p>Luxembourg/Luxemburg 
Chiesi sa/nv 
Tél/Tel: + 32 (0)2 788 42<br />
Česká republika 
Chiesi CZ s.r.o. 
Tel: + 420 261221 
Magyarország 
Chiesi Hungary Kft. 
Tel.: + 36-1-429 1 
Danmark 
Chiesi Pharma AB 
Tlf: + 46 8 753 35<br />
Malta 
Chiesi Farmaceutici S.p.A. 
Tel: + 39 0521 2 
Deutschland 
Chiesi GmbH 
Tel: + 49 40 89724-0 </p>
<p>Nederland 
Chiesi Pharmaceuticals B.V. 
Tel: + 31 88 501 64<br />
Eesti 
Chiesi Pharmaceuticals GmbH 
Tel: + 43 1 4073 
Norge 
Chiesi Pharma AB 
Tlf: + 46 8 753 35<br />
Ελλάδα 
DEMO ABEE 
Τηλ: + 30 210 8161 
Österreich 
Chiesi Pharmaceuticals GmbH 
Tel: + 43 1 4073 
España 
Chiesi España, S.A.U. 
Tel: + 34 934948 
Polska 
Chiesi Poland Sp. z.o.o. 
Tel.: + 48 22 620 1 
France 
Chiesi S.A.S.<br />
Tél: + 33 1 47688899  </p>
<p>Portugal 
Chiesi Farmaceutici S.p.A. 
Tel: + 39 0521 2 
Hrvatska 
Chiesi Pharmaceuticals GmbH 
Tel: + 43 1 4073 
România 
Chiesi Romania S.R.L. 
Tel: + 40 212023 
Ireland 
Chiesi Farmaceutici S.p.A. 
Tel: + 39 0521 2 
Slovenija 
CHIESI SLOVENIJA, d.o.o. 
Tel: + 386-1-43 00<br />
Ísland 
Chiesi Pharma AB 
Sími: +46 8 753 35<br />
Slovenská republika 
Chiesi Slovakia s.r.o. 
Tel: + 421 259300 
Italia 
Chiesi Italia S.p.A. 
Tel: + 39 0521 2 
Suomi/Finland 
Chiesi Pharma AB 
Puh/Tel: +46 8 753 35<br />
Κύπρος 
The Star Medicines Importers Co. Ltd. 
Τηλ: + 357 25 371 
Sverige 
Chiesi Pharma AB 
Tel: +46 8 753 35<br />
Latvija 
Chiesi Pharmaceuticals GmbH 
Tel: + 43 1 4073 
United Kingdom (Northern Ireland) 
Chiesi Farmaceutici S.p.A. 
Tel: + 39 0521 2 </p>
<p>Denne indlægsseddel blev senest ændret . </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>
<p>Indlægsseddel: Information til brugeren </p>
<p>Ferriprox 100 mg/ml oral opløsning 
deferipron </p>
<p>Læs denne indlægsseddel grundigt, inden du begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. 
− 
Gem indlægssedlen. Du kan få brug for at læse den igen. 
− 
Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide. 
− 
Lægen har ordineret dette lægemiddel til dig personligt. Lad derfor være med at give medicinen 
til andre. Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har. 
− 
Kontakt lægen eller apotekspersonalet, hvis du får bivirkninger, herunder bivirkninger, som ikke 
er nævnt i denne indlægsseddel. Se punkt 4. − 
Et patientkort er påsæt æsken. Tag kortet af, udfyld det, læs patientkortet omhyggeligt og sørg 
for at have det på dig. Vis dette patientkort til lægen, hvis du udvikler symptomer på infektion, 
f.eks. feber, ondt i halsen eller influenzalignende symptomer. </p>
<p>Se den nyeste indlægsseddel på www.indlaegsseddel.dk. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-174da4bc3583312132255c6ab13da6ac
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for ferriprox Package Leaflet for language en"
Description: "ePI document Bundle for ferriprox Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-174da4bc3583312132255c6ab13da6ac"
* entry[0].resource = composition-en-174da4bc3583312132255c6ab13da6ac

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp174da4bc3583312132255c6ab13da6ac"
* entry[=].resource = mp174da4bc3583312132255c6ab13da6ac
                            
                    
Instance: bundlepackageleaflet-da-174da4bc3583312132255c6ab13da6ac
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for ferriprox Package Leaflet for language da"
Description: "ePI document Bundle for ferriprox Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-174da4bc3583312132255c6ab13da6ac"
* entry[0].resource = composition-da-174da4bc3583312132255c6ab13da6ac

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp174da4bc3583312132255c6ab13da6ac"
* entry[=].resource = mp174da4bc3583312132255c6ab13da6ac
                            
                    



Instance: mp174da4bc3583312132255c6ab13da6ac
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Ferriprox 500 mg film-coated tablets"
Description: "Ferriprox 500 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Ferriprox 500 mg film-coated tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Ferriprox 500 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 174da4bc3583312132255c6ab13da6acListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "ferriprox"

* status = #current
* mode = #working

* title = "List of all ePIs associated with ferriprox"

* subject = Reference(mp174da4bc3583312132255c6ab13da6ac)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#ferriprox "ferriprox"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-174da4bc3583312132255c6ab13da6ac) // ferriprox en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-174da4bc3583312132255c6ab13da6ac) // ferriprox da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-174da4bc3583312132255c6ab13da6ac
InstanceOf: List

* insert 174da4bc3583312132255c6ab13da6acListRuleset
    